Navigation Links
TGen Drug Development establishes European footprint
Date:11/19/2009

SCOTTSDALE, Ariz. Nov. 18, 2009 TGen Drug Development (TD2) and the Institut Paoli-Calmettes (IPC) have forged a strategic alliance that will enable both to maximize their worldwide contributions in the treatment of cancer patients.

The partnership between TD2, a Scottsdale subsidiary of the Phoenix-based Translational Genomics Research Institute (TGen), and Marseille, France-based IPC's comprehensive cancer center will enable both non-profit institutes to speed research discoveries to patients with cancer.

Both organizations will expand their clinical research network to evaluate new therapies in the U.S. and Europe in an effort to more quickly introduce new drugs into clinical trials.

Teams from both TD2 and IPC will focus their efforts on discovering molecular alterations within cancers and finding biomarkers that will help identify new therapeutic targets that can be used to tailor treatments for individual patients.

IPC and TD2 will collaborate on a number of primary tumor and metastasis in selected cancers, as well as initiate an exchange program for medical oncologists between the two institutions.

"Aligning with IPC represents a significant opportunity for TD2 and TGen to further expand our research affiliations into Europe," said Dr. Daniel Von Hoff, TGen's Physician-In-Chief. "In addition to our ongoing collaborations with Luxembourg, this new alliance with IPC will further our goals across both Europe and the United States of providing better treatments in a more timely fashion to our many patients who suffer from a variety of cancer types."

Professor Patrice Viens, a medical oncologist and General Director of IPC, said the alliance with TD2 will enable IPC to bridge new international relationships: "This alliance with TD2 translates to our continuing efforts to expand our collaborations in basic research and medical activities beyond Europe.''

IPC is one of the largest university-affiliated comprehensive cancer centers in France, involved in the management of nearly 6,000 new cases of cancer each year. IPC established a Biological Resource Center (BRC) in oncology that has 70,000 tumor and biological fluid samples, mostly of breast, pancreatic and blood cancers. ICP had more than 600 patients in clinical trials during 2008.

IPC is affiliated with the Ovarian Cancer Diagnosis Initiative (OVCAD), which is dedicated to ovarian cancer research, and with the European Consortium for Anticancer Antibody Development (EUCAAD), a European consortium dedicated to anti-angiogenic treatments. It also is involved in collaborations with biotech and pharmaceutical companies.

IPC will join TGen's Pancreatic Cancer Research Team (PCRT), which includes other U.S. and international researchers.

"Our meetings at TGen have confirmed our decision to team up with this premier organization on the cutting edge of research and pharmacogenomics in oncology," Professor Viens said. "In addition we are thrilled to work again with Dr. Von Hoff." Professor Viens and Dr. Von Hoff once worked together at the University of Texas Health Science Center in San Antonio, Texas.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. Gender, coupled with diabetes, affects vascular disease development
2. New target for anti-flu drug development
3. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
4. KAUST and American University in Cairo to collaborate on research and academic development
5. Old developmental pathways spawn revolutionary evolutionary changes
6. NIST announces 56 new awards for innovative technology research and development
7. Progress Against Malaria: Developments on the Horizon
8. Flu vaccine in painless skin patches under development at Emory, Georgia Tech with NIH grants
9. Biopharmaceutical infrastructure key to lower drug development costs
10. Study identifies pathway required for normal reproductive development
11. 200 journals join in theme issues on poverty and human development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/10/2017)... DUBLIN , Feb 10, 2017 ... PharmaBiotech,s new report "Personalized Medicine - Scientific and Commercial ... ... in personalized medicine. Diagnosis is integrated with therapy for selection ... emphasis on early detection and prevention of disease in modern ...
(Date:2/8/2017)... 7, 2017  Aware, Inc. (NASDAQ: AWRE ), ... financial results for its quarter and year ended December 31, ... 2016 was $3.9 million compared to $6.9 million in the ... of 2016 was $0.6 million compared to $2.6 million in ... quarter of 2016 was $0.5 million, or $0.02 per diluted ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... February 24, 2017 , ... FireflySci, Inc is an ... late 2014, FireflySci had the goal of bringing their powerful cuvette and ... shape the path that FireflySci is going on as they add yet another mark ...
(Date:2/23/2017)... Financial Highlights (in ... Months Ended December 31,Twelve Months Ended December 31,20162015% ... $           300$     ... Revenue 3539(10)%9498(4)%Kuvan Net Product Revenue ... 756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... 2017  Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, ... a head lice treatment salon to set up shop. But ... and a French bistro on E Madison Ave, and CEO ... any old lice clinic, we pride ourselves on being a ... some of the stigma associated with lice. Everyone can get ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can fast-track sample ... acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. ... the relationship between insulin and other relevant biomarkers can be extensively studied through ...
Breaking Biology Technology: